The central focus of Dr. Lindsley's laboratory is on myeloid malignancies [such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)] and bone marrow failure syndromes. His lab uses genomic technologies to study samples from patients with these diseases as a way to define pathways of disease initiation and progression, and to identify mutations that predict outcomes after various treatments. He uses mouse and cell line models to dissect the mechanisms by which these gene mutations cause disease.
Dana Farber Cancer Institute:
450 Brookline Ave, Boston, MA 02215, USA
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life
AML stories, AML clinical trials, AML 101 articles and events with AML
Thanks to our HealthTree Community for AML Sponsors: